Crohn's Disease Treatment Forecast Report 2025 – Designed for Product & Growth Teams

 We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

 
 What is the current market size of the crohn’s disease treatment industry, and what growth rate is it expected to achieve?
 The crohn’s disease treatment market size has grown strongly in recent years. It will grow from$12.45 billion in 2024 to $13.23 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased disease prevalence, advancements in diagnostic techniques, biological therapies adoption, patient awareness and education, clinical research and development
 
 The crohn’s disease treatment market size is expected to see strong growth in the next few years. It will grow to “$17.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine approaches, biologics market expansion, evolving treatment guidelines, increased healthcare spending, collaborative research efforts. Major trends in the forecast period include telemedicine for patient management, research on immune modulation strategies, patient-centric care models, integration of digital health solutions.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp
 
 What are the major drivers contributing to the growth of the crohn’s disease treatment market?
 The increase in the prevalence of inflammatory bowel disorders is expected to propel the growth of the Crohn’s disease treatment market going forward. Inflammatory bowel disorders refer to a group of chronic conditions involving gastrointestinal tract inflammation. It can cause inflammation and damage to any part of the digestive system, from the mouth to the anus. Crohn’s disease helps by decreasing the inflammation of the intestine, to prevent flare-ups of symptoms, and to keep in remission. For instance, in September 2023, according to the National Center for Biotechnology Information, a US-based government organization, the prevalence of Crohn’s disease and ulcerative colitis has similarly increased, with inflammatory bowel disease projected at 825 cases per 100,000 people in 2023–410 for Crohn’s disease and 414 for ulcerative colitis and IBD-u. As a result, the rising prevalence of these disorders is fueling the expansion of the Crohn’s disease treatment market.
 
 What are the major market segments driving the growth of the crohn’s disease treatment industry?
 The crohn’s disease treatment market covered in this report is segmented –
 
 1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications
 
 Subsegments:
 1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
 2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
 3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
 4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
 5) By Other Drug Types: Biologics, Small Molecules, Other Treatments
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
 
 How are emerging trends transforming the crohn’s disease treatment market dynamics?
 Major companies operating in the crohn’s disease treatment market are innovating new drugs and getting them approved, such as biosimilar ustekinumab, to provide more effective and accessible treatment options for patients, ultimately improving patient outcomes and quality of life. Biosimilar ustekinumab refers to a biologic drug highly similar to the original ustekinumab (a monoclonal antibody) used for treating autoimmune conditions. For instance, in July 2024, Sandoz International GmbH, a Switzerland-based pharmaceutical company, launched Pyzchiva (ustekinumab) across Europe, marking it as the first ustekinumab biosimilar available in all strengths, including a 130 mg vial specifically for Crohn’s disease. This product is indicated for adults and children over six with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, enhancing Sandoz’s immunology portfolio while aiming to improve access to affordable treatments for chronic inflammatory disease.
 
 Who are the key market players contributing to the growth of the crohn’s disease treatment industry?
 Major companies operating in the crohn’s disease treatment market include AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Bristol-Myers Squibb Company, Galapagos NV, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Arena Pharmaceuticals Inc.
 
 Which regions are leading the growth of the crohn’s disease treatment market globally?
 North America was the largest region in the global Crohn’s disease treatment market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the Crohn’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 How Can Companies Use The Crohn’s Disease Treatment Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10852
 
 Need Customized Data On Crohn’s Disease Treatment Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=10852&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company